Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

PURPOSE: We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor. METHODS: Patie...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Chesney, Jason, Puzanov, Igor, Collichio, Frances, Singh, Parminder, Milhem, Mohammed M., Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore F., Hauschild, Axel, Lebbé, Celeste, Chen, Lisa, Kim, Jenny J., Gansert, Jennifer, Andtbacka, Robert H.I., Kaufman, Howard L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
Rapid Communications
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075852/
https://ncbi.nlm.nih.gov/pubmed/28981385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.7379
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi